EGFR and non-small cell lung carcinoma: This study also showed that treating cultured EGFRM+ NSCLC cells with osimertinib resulted in AXL upregulation as well as interaction with EGFR and ERBB3, which in turn contributed to maintaining cell survival and to the emergence of osimertinib-tolerant cells.